港股異動丨智雲健康拉昇升超18%
智雲健康(9955.HK)午後出現明顯拉昇走勢,盤中一度升超18%至2.86港元,成交額放大至逾5200萬港元。公司此前在3月21日公佈的業績顯示,2023年收入保持高速增長態勢,營業收入同比增長23.5%至36.9億元。其中,院內解決方案收入28.7億元,佔比超過七成,是最大收入來源,同比增長31.5%;藥店解決方案收入6.6億元,同比增長6.9%;個人慢病管理解決方案及其他收入1.6億元。非國際財務報吿準則(Non-IFRS)調整後淨虧損收窄至7510萬元,同比收窄77.4%。2023年第四季度成為公司首個盈利季度,實現單季度扭虧為盈。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.